Trial · NCT03013543
Results by group512
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 512
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With ≥ 5% Reduction in Body Weight From Baseline After 3 Months of Setmelanotide Treatment | 16p11.2 Cohort | 6 | Participants | ||
| Number of Participants With ≥ 5% Reduction in Body Weight From Baseline After 3 Months of Setmelanotide Treatment | AS Cohort | 3 | Participants | ||
| Number of Participants With ≥ 5% Reduction in Body Weight From Baseline After 3 Months of Setmelanotide Treatment | BBS Cohort | 7 | Participants | ||
| Number of Participants With ≥ 5% Reduction in Body Weight From Baseline After 3 Months of Setmelanotide Treatment | MC4R Cohort | 7 | Participants | ||
| Number of Participants With ≥ 5% Reduction in Body Weight From Baseline After 3 Months of Setmelanotide Treatment | POMC/PCSK1/LEPR Heterozygous Cohort | 10 | Participants | ||
| Number of Participants With ≥ 5% Reduction in Body Weight From Baseline After 3 Months of Setmelanotide Treatment | POMC/PCSK1/LEPR Composite Heterozygous Cohort | 0 | Participants | ||
| Number of Participants With ≥ 5% Reduction in Body Weight From Baseline After 3 Months of Setmelanotide Treatment | POMC/PCSK1/LEPR Compound Heterozygous Cohort | 14 | Participants | ||
| Number of Participants With ≥ 5% Reduction in Body Weight From Baseline After 3 Months of Setmelanotide Treatment | SH2B1 Cohort | 8 | Participants | ||
| Number of Participants With ≥ 5% Reduction in Body Weight From Baseline After 3 Months of Setmelanotide Treatment | SMS Cohort | 1 | Participants | ||
| Number of Participants With ≥ 5% Reduction in Body Weight From Baseline After 3 Months of Setmelanotide Treatment | SRC1 Cohort | 9 | Participants | ||
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 16p11.2 Cohort | 19 | Participants | ||
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | AS Cohort | 4 | Participants | ||
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | BBS Cohort | 10 | Participants | ||
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | MC4R Cohort | 49 | Participants | ||
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | POMC/PCSK1/LEPR Heterozygous Cohort | 33 | Participants | ||
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | POMC/PCSK1/LEPR Composite Heterozygous Cohort | 5 | Participants | ||
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | POMC/PCSK1/LEPR Compound Heterozygous Cohort | 27 | Participants | ||
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | SH2B1 Cohort | 21 | Participants | ||
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | SMS Cohort | 12 | Participants | ||
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | SRC1 Cohort | 29 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03013543/results